Recent Updates
Recently added Catalysts
AUPH Positive Sentiment

Aurinia Pharmaceuticals Reports Financial Results for the Three and Nine Months Ended September 30, 2026 and Provides Update on Recent Business Progress

Friday, October 30, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Aurinia Pharmaceuticals reported financial results for Q3 and nine months ended September 30, 2026. Total revenue reached $83.7 million for the quarter, marking a 14% increase from the previous year. For the nine-month period, revenue was $244.6 million, a 19% rise. The company also shared updates on its business progress.

Market Sentiment Analysis

POSITIVE FACTORS

  • Total revenue increased by 14% for Q3 2026.
  • Net product sales showed significant growth.
  • Company provided a positive update on business progress.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+63%
120-day peak, hindsight
Typical move
8.6%
average across 2 past catalysts
Lead asset
Aritinercept
Phase 1 · Myasthenia Gravis, Generalized

Full Press Release Details

EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced financial results for the three and nine months ended September 30, 2026 and provided an update on recent business progress. Financial Results Total Revenue: For the three and nine months ended September 30, 2026, total revenue was $83.7 million and $244.6 million, up 14% and 19%, respectively, from $73.5 million and $205.9 million, respectively, in the same periods of 2025. Net Product Sales: For th

Frequently Asked Questions

What were Aurinia's total revenues for Q3 2026?

Total revenues for Q3 2026 were $83.7 million.

How much did revenue increase compared to Q3 2025?

Revenue increased by 14% compared to Q3 2025.

What was the revenue for the nine months ended September 30, 2026?

Revenue for the nine months was $244.6 million.

Did Aurinia provide any updates on business progress?

Yes, the company provided a positive update on recent business progress.

ShareAdd on Google
Tags: AUPH Aurinia Pharmaceuticals financial results revenue growth Q3 2026
Last updated: Oct 30, 2026

Biotech snapshot

Cash runway
$487M liquidity · $0M/mo burn
Low dilution risk
Lead asset
AritinerceptPhase 1
Myasthenia Gravis, Generalized →

Catalyst track record

+63%
best trade around AUPH's most recent catalyst

Peak hindsight return over a 120-day window, across 2 tracked FDA/PDUFA catalysts for AUPH.

See every catalyst's timing & PoA →